BELLEVUE, Wash., July 7 Light Sciences Oncology, Inc.(LSO) today announced that it has begun treatment of patients with benignprostatic hyperplasia (BPH), or enlargement of the prostate, using LightInfusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatmentunder development. LSO plans to conduct a 12-patient, Phase I/IIdose-escalation study at four sites in the United States as well as a40-patient, Phase IIa study in Australia, expected to begin during the currentquarter.
"Treating patients with this serious quality-of-life problem is animportant milestone for our Litx technology," said Llew Keltner, M.D., Ph.D.,President and Chief Executive Officer of LSO. "We plan to continue todemonstrate the broader applicability of Litx beyond oncology." LSO currentlyis conducting Phase III clinical studies of Litx in patients with hepatoma(primary liver cancer) and metastatic colorectal cancer and expects toinitiate a Phase III clinical study in glioma in the second half of 2008.
BPH is a common result of aging and is estimated to occur in more than 14million American men. BPH rarely causes symptoms before age 40, but more thanhalf of men in their sixties and as many as 90 percent in their seventies andeighties have some symptoms of BPH, which typically include painful andfrequent urination caused by the enlarged prostate's reduction of urine flowthrough the urethra. Early stage treatment is critical, because severe BPHcan cause serious problems over time, such as urinary tract infections,bladder stones, incontinence, and eventually untreatable bladder or kidneydamage.
Litx uses light-emitting diodes (LEDs) to activate LS11 (talaporfinsodium) molecules. Once activated, these molecules cause the production ofsinglet oxygen, which can kill target tissues with minimal side effectsthrough vascular closure and apoptosis, or "programmed cell death." Thesingle-use, disposable Litx device contains a tiny array of LEDs.
In the Litx BPH application, a modified standard urethral catheterpositions the proprietary light-emitting LED array precisely within theprostate. After systemic injection of LS11, the LEDs are turned on, andactivation of the drug occurs locally within the prostate. When the shorttreatment is complete, the LED-containing catheter is removed and thrown away.The goal of the therapy is to kill prostate tissue via apoptosis within ahighly localized zone in the prostate, without causing inflammation. Theshort, single outpatient treatment is designed to effectively re-establish andmaintain an unobstructed urine flow, relieving BPH symptoms.
ABOUT LIGHT SCIENCES ONCOLOGY
Light Sciences Oncology, Inc. (LSO) is developing Light InfusionTherapy(TM) (Litx(TM)) to provide safer and more effective treatment forcancer and other conditions. In addition to the Phase III trials inhepatocellular carcinoma and colorectal cancer metastatic to the liver, theCompany has completed a Phase II clinical trial of Litx in glioma and plans toinitiate a Phase III trial in glioma during the second half of 2008. LSO haswidened the scope of potential therapeutic applications of the versatile Litxplatform to include benign neoplasms such as benign prostatic hyperplasia(BPH), neurofibromas, and uterine fibroids, as well as vascular disease anddermatology. The Company has positioned itself for growth with a strongportfolio of intellectual property, innovative applications in development,and an exceptionally talented team.
Light Infusion Therapy(TM) and Litx(TM) are trademarks of Light SciencesOncology, Inc.Contact: Robert M. Littauer Vice President, Chief Financial Officer and Treasurer 425-957-8900 firstname.lastname@example.org Llew Keltner, M.D., Ph.D. President and CEO 425-957-8900 email@example.com website: www.lsoncology.com
SOURCE Light Sciences Oncology, Inc.